ストックスクリーナーアプリを入手
0.404
10.22%
-0.046
アフターアワーズ：
.42
0.016
+3.96%
前日終値:
$0.45
開ける：
$0.45
24時間の取引高:
1.05M
Relative Volume:
2.97
時価総額：
$46.69M
収益：
-
当期純損益:
$-168.86M
株価収益率:
-0.2257
EPS:
-1.79
ネットキャッシュフロー:
$-125.29M
1週間 パフォーマンス:
-10.22%
1か月 パフォーマンス:
-29.14%
6か月 パフォーマンス:
-45.34%
1年 パフォーマンス:
-81.80%
1日の値動き範囲:
$0.404
$0.4746
1週間の範囲:
$0.4021
$0.48
52週間の値動き範囲:
$0.4021
$2.36
Allovir Inc Stock (ALVR) Company Profile
ALVR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALVR
Allovir Inc
|
0.404 | 46.69M | 0 | -168.86M | -125.29M | -1.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allovir Inc Stock (ALVR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-26 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-12-22 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2023-12-22 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-12-22 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-08-18 | 開始されました | BofA Securities | Buy |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2020-08-24 | 開始されました | JP Morgan | Overweight |
| 2020-08-24 | 開始されました | Morgan Stanley | Overweight |
| 2020-08-24 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Allovir Inc (ALVR) 最新ニュース
AlloVir appoints new CEO following leadership shakeup By Investing.com - Investing.com South Africa
AlloVir appoints new CEO following leadership shakeup - Investing.com India
AlloVir CEO Departs, CFO Steps In - MarketWatch
AlloVir Appoints Vikas Sinha as New CEO - TipRanks
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALVR, CDMO, EMKR on Behalf of Shareholders - The Eastern Progress Online
Allovir stock touches 52-week low at $0.47 amid market challenges - Investing.com
AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update - MarketBeat
AlloVir (NASDAQ:ALVR) Stock Price Down 1.2%What's Next? - MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AlloVir, Inc. (NasdaqALVR), EMCORE Corporation (NasdaqEMKR), Staffing 360 Solutions, Inc. (NasdaqSTAF), Adams Resources & Energy, Inc. (NYSE American - GlobeNewswire Inc.
Epstein-Barr Virus (EBV) Market A Deep Dive into Current - openPR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENLC, ALVR, CYTH on Behalf of Shareholders - GlobeNewswire Inc.
Influenza Pipeline Insights 2024: Therapies, Clinical Trials, - openPR
Allovir stock hits 52-week low at $0.5 amid market challenges By Investing.com - Investing.com South Africa
Allovir stock hits 52-week low at $0.5 amid market challenges - Investing.com Nigeria
Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead - Scrip
Allovir stock plunges to 52-week low, touches $0.51 By Investing.com - Investing.com Canada
Allovir stock plunges to 52-week low, touches $0.51 - Investing.com
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of INSI, LBRDA, ROIC and ALVR - The Malaysian Reserve
Finansavisen - Finansavisen
AlloVir falls after all-stock merger deal with Kalaris - MSN
AlloVir to combine with Kalaris Therapeutics in all-stock transaction - MSN
ROSEN, LEADING TRIAL ATTORNEYS, Encourages AlloVir, Inc. Investo - GuruFocus.com
AlloVir, Inc. (NASDAQ:ALVR) Sees Significant Drop in Short Interest - MarketBeat
AlloVir Ditches Immunotherapy, Teams Up with Kalaris to Take Over the $14 Billion Retinal Market - BSA bureau
Allovir stock plunges to 52-week low of $0.58 amid market challenges - Investing.com India
$hareholder Alert: The M&A Class Action Firm Launches Legal Inquiry the Merger ROIC, VINE, ALVR and CDMO - AccessWire
AlloVir and Kalaris enter merger to advance retinal disease therapies - Pharmaceutical Technology
AlloVir and Kalaris Therapeutics Announce Merger - FinSMEs
$hareholder Alert: The M&A Class Action Launches Legal Inquiry for the Merger of ROIC, VINE, ALVR and CDMO - AccessWire
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc.ALVR - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders - GlobeNewswire
ROIC, VINE, ALVR and CDMO Alert: The M&A Class Action Firm Continues to Investigate the Merger - AccessWire
Items Tagged with 'TH-103' - BioWorld Online
With Eylea rival in clinic, once-stealthy Kalaris finds public path via merger - BioCentury
Items Tagged with 'Kalaris Therapeutics Inc.' - BioWorld Online
Allovir sees a new direction with Kalaris merger - BioWorld Online
SEC Form 425 filed by AlloVir Inc. - Quantisnow
Kalaris to go public via reverse merger with AlloVir - BioPharma Dive
AlloVir announces merger with Kalaris Therapeutics - The Pharma Letter
Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian
ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders - Business Wire
Allovir Inc (ALVR) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):